Antisynthetase syndrome

4 trials 2 recruiting MedDRA PT
4 Registered trials
2 Recruiting
3 Unique sponsors
4 Unique IMPs
1 Commercial trials
Drug classes (ATC)
H Endocrinology (ATC H) 1
L Oncology (ATC L) 3
Mechanism of action (INN-stem analysis)
Monoclonal antibody (immune) 1 substance
Corticosteroid 1 substance
JAK inhibitor 1 substance
EGFR inhibitor 1 substance
Phase II: 4

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase II

4 trials
  • Horizon Therapeutics Ireland Designated Activity Company Commercial
    DAXDILIMAB; PREDNISONE
    2022-502810-10-00 5 countries 2023 n=26
    Ended
  • Medical University Of Vienna Academic
    UPADACITINIB
    2024-513681-19-00 1 country 2025 n=10
    Recruiting
  • University Medical Center Utrecht Academic
    FILGOTINIB
    2022-502968-20-01 1 country n=60
    Not authorised
  • University Medical Center Utrecht Academic
    FILGOTINIB
    2022-502968-20-02 1 country 2024 n=40
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
University Medical Center Utrecht Academic 2 Phase II 1
Horizon Therapeutics Ireland Designated Activity Company Commercial 1 Phase II 0
Medical University Of Vienna Academic 1 Phase II 1
New trials by year
2023
1
2024
1
2025
1
← All indication landscapes